AMICUS THERAPEUTICS, INC. — Director's Dealing 2020

Oct 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2020-10-01

Reporting Person: Quimi Daphne (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-01	Common Stock	M	5000	$2.94	Acquired	212179	Direct
2020-10-01	Common Stock	S	5000	$14.0198	Disposed	207179	Direct
2020-10-02	Common Stock	M	11000	$2.45	Acquired	218179	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-01	Stock Options (right to buy)	$2.94	M	5000	Disposed	2024-06-26	Common Stock (5000)	Direct
2020-10-02	Stock Options (right to buy)	$2.45	M	11000	Disposed	2024-01-03	Common Stock (11000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.87 to $14.31. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of the options were fully vested and exercisable as of the transaction date.